With the newly introduced TNI®softFlow systems, TNI medical AG maximizes patient comfort and compliance with provision of full respiratory support, leading to greater cost efficiencies.

COPD is one of the most serious chronic diseases. According to the WHO there are 80m diagnosed COPD patients worldwide of an estimated total of approx. 400m and it will become the 3rd leading cause of death by 2020.

HFNC has significant benefits compared to traditional NIV, which are verified by an increasing number of clinical studies and is ideally positioned to become the next first-line therapy for COPD.

TNI®softFlow supplies the patient with a constant, warm and humidified air flow, if necessary combined with oxygen, by a thin sound optimized nasal prong applicator. This leads to an improvement of ventilation with a high therapy acceptance and excellent therapy results for Respiratory Diseases.